BioPharmSignal logoBioPharmSignal

Biotech News

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

RxSight (RXST)RxSightEarnings

ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results

Related news

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

RXSTRxSight2026-08-05 20:05 EST

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

STIMNeuronetics2026-08-11 11:50 EST

Neuronetics Reports Second Quarter 2026 Financial and Operating Results

CVRXCVRx2026-08-06 20:05 EST

CVRx Reports Second Quarter 2026 Financial and Operating Results

STIMNeuronetics2026-07-28 12:30 EST

Neuronetics to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call

CVRXCVRx2026-07-23 20:30 EST

CVRx to Report Second Quarter 2026 Financial and Operating Results and Host Conference Call on August 6, 2026

IRIXIRIDEX2026-08-18 20:05 EST

Iridex Reports Second Quarter 2026 Financial Results

SGHTSight Sciences2026-08-05 20:05 EST

Sight Sciences Reports Second Quarter 2026 Financial Results

IRIXIRIDEX2026-08-04 20:05 EST

Iridex to Report Second Quarter 2026 Financial Results on August 18, 2026

ADPTAdaptive Biotechnologies2026-07-29 20:05 EST

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

View all latest news

RxSight

Adjustable Cataract Lenses RxSight is an ophthalmic medical-device company focused on customized vision after cataract surgery. Light Adjustable Lens System The system combines an implantable Light Adjustable Lens with a Light Delivery Device. After surgery, physicians use ultraviolet light treatments to modify the lens and refine the...

Recent company news

RXSTRxSight2026-08-05 20:05 EST

RxSight, Inc. Reports Second Quarter 2026 Results and Provides Update on 2026 Outlook

RXSTRxSight2026-07-26 20:00 EST

RxSight Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

RXSTRxSight2026-07-15 20:15 EST

RxSight Announces Appointments of Aziz Mottiwala as Chief Executive Officer and Ron Kurtz, M.D. as Chief Medical Officer

RXSTRxSight2026-07-06 20:16 EST

Alcon and RxSight Announce Collaboration to Develop Adjustable PCIOLs

RXSTRxSight2026-07-06 20:15 EST

RxSight, Inc. Announces Preliminary Second Quarter Financial Results and Product Pipeline Updates Following Strategic Collaboration Agreement

Stock data

Close
6.25 USD
Market cap
204.5M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States